WebFeb 7, 2024 · Press Release Daré Bioscience to Participate in Upcoming Conferences. 02-07-2024 at 8:00 AM EST. PDF Version. SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, ... WebMar 17, 2024 · Scrip Asks…What Does 2024 Hold For Biopharma? Part 8: Therapeutic Area Advances (Subscription required)
Did you know?
WebFeb 5, 2024 · SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2024, at 11:00 a.m. Eastern Time at the … WebSep 1, 2024 · SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from the company’s Phase 1 pharmacokinetic and safety study of DARE-HRT1 at the European Menopause …
WebMar 31, 2024 · Press Release Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV) 03-31-2024 at 7:00 AM EDT PDF Version An estimated 21 million American women experience … WebJan 9, 2024 · Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that … This section contains both current and archived webcasts and presentations of … The Investor Relations website contains information about Daré Bioscience's …
WebDec 31, 2024 · SAN DIEGO, March 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2024, to review its financial results for the year ended December 31, 2024 and to provide … WebMar 1, 2024 · SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35 th Annual Roth Conference, being held March 12-14, 2024 in Laguna Niguel, CA.
WebMar 30, 2024 · SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the year ended December 31,...
WebJun 30, 2024 · Press Release Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides a Company Update 08-09-2024 at 8:00 AM EDT PDF Version June 30, 2024: $32.1 million in cash and cash equivalents July 2024: approximately $18.0 million in cash received subsequent to quarter-end: the point venice flWebDec 7, 2024 · SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA)... the point video harry nilssonWebMar 29, 2024 · Scrip Asks…What Does 2024 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion (Subscription required) the point videosidharth antakhyari full 20WebApr 5, 2024 · April 5, 2024, 7:46 PM · 25 min read. Daré Bioscience, Inc. (NASDAQ: DARE) Q4 2024 Earnings Call Transcript March 30, 2024. Operator: Welcome to the conference call hosted by Daré Bioscience ... sidhartha münchenWebJan 13, 2024 · Press Release Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone … the point vitalsourceWeb11-50 Employees. Based in San Diego, California. Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to … the point wadmalaw